Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Equity Ratio (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Equity Ratio readings, the most recent being 0.63 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 37.37% to 0.63 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.63, a 37.37% increase, with the full-year FY2025 number at 0.63, up 37.37% from a year prior.
  • Equity Ratio hit 0.63 in Q4 2025 for Arcadia Biosciences, roughly flat from 0.63 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.78 in Q1 2022 to a low of 0.46 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.66 (2023), compared with a mean of 0.66.
  • Biggest five-year swings in Equity Ratio: surged 91.69% in 2021 and later dropped 29.58% in 2023.
  • Arcadia Biosciences' Equity Ratio stood at 0.71 in 2021, then grew by 1.73% to 0.72 in 2022, then decreased by 10.79% to 0.64 in 2023, then fell by 28.58% to 0.46 in 2024, then skyrocketed by 37.37% to 0.63 in 2025.
  • The last three reported values for Equity Ratio were 0.63 (Q4 2025), 0.63 (Q3 2025), and 0.58 (Q2 2025) per Business Quant data.